Filtered By:
Procedure: Pulmonary Function Testing

This page shows you your search results in order of date. This is page number 10.

Order by Relevance | Date

Total 287 results found since Jan 2013.

Severe asthma concomitant with allergic bronchopulmonary aspergillosis (ABPA) and non-steroid exacerbated respiratory disease (N-ERD) successfully treated with mepolizumab: A case report
Tuberk Toraks. 2022 Jun;70(2):215-219. doi: 10.5578/tt.20229815.ABSTRACTAllergic bronchopulmonary aspergillosis (ABPA) is a lung disease characterized by a hypersensitivity reaction to Aspergillus fumigatus. Allergic bronchopulmonary aspergillosis is characterized by increased serum IgE levels, peripheral blood eosinophilia and radiographic pulmonary infiltrates, central bronchiectasis, and mucus plugs. Mepolizumab, a monoclonal interleukin (IL)-5 antibody, reduces eosinophilic inflammation and improves symptom control in severe eosinophilic asthma. A 74-year-old male patient arrived at our allergy outpatient clinic compla...
Source: Tuberkuloz ve Toraks - July 5, 2022 Category: Respiratory Medicine Authors: Mehmet Erdem Çakmak Source Type: research

Pulmonary function testing for the diagnosis of asthma in preschool children
Purpose of review To highlight the recent evidence of the lung function techniques used in preschool children to diagnose asthma. Recent findings Several techniques are available to measure lung function and airway inflammation in preschool children, including spirometry (from age 5 years), impulse oscillometry (>3 years), whole-body plethysmography (>3 years), fractional exhaled nitric oxide (FeNO) (>5 years), multiple breath washout (>3 years), structured light plethysmography (>1–2 years) and impedance pneumography (>1 years). If applicable, measuring forced expiratory volume in 1 s (FEV1) and...
Source: Current Opinion in Allergy and Clinical Immunology - February 24, 2022 Category: Allergy & Immunology Tags: PEDIATRIC ASTHMA AND DEVELOPMENT OF ATOPY: Edited by Pasquale Comberiati Source Type: research

Mepolizumab Is an Effective Option in Severe Eosinophilic Asthma Regardless of Baseline Features: Single-Center Real-Life Data
Conclusion: Mepolizumab effectively reduced asthma exacerbations, steroid requirement, blood eosinophil counts and improved asthma control, pulmonary function, sinonasal symptoms and quality of life. Our data suggest that mepolizumab would be effective in selected patients in real-life settings.Int Arch Allergy Immunol
Source: International Archives of Allergy and Immunology - December 14, 2021 Category: Allergy & Immunology Source Type: research

Occupational exposure as a predictor of asthma exacerbation - a multicenter multivariate logistical analysis
Conclusion: More than one third of patients had uncontrolled asthma. One of the strongest predictors for exacerbation is occupational exposure.
Source: European Respiratory Journal - November 25, 2021 Category: Respiratory Medicine Authors: Mihaicuta, S., Udrescu, L., Tiotiu, A., Nadasan, V., Frent, S. M. Tags: Occupational and environmental health Source Type: research